[
    [
        {
            "time": "",
            "orginal_text": "白云山(00874)附属收到苯甲酸雌二醇注射液等36个药品的《药品再注册批件》",
            "features": {
                "keywords": [
                    "白云山",
                    "药品再注册",
                    "苯甲酸雌二醇注射液",
                    "36个药品"
                ],
                "sentiment_score": 0.7,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "original_text": "白云山(00874)附属收到苯甲酸雌二醇注射液等36个药品的《药品再注册批件》",
            "scores": {
                "News_content": "白云山(00874)附属收到苯甲酸雌二醇注射液等36个药品的《药品再注册批件》",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 6,
                "Headline_Structure": 6,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "orginal_text": "白云山(00874.HK)：全资子公司收到36个药品再注册批件",
            "features": {
                "keywords": [
                    "白云山",
                    "药品再注册",
                    "全资子公司",
                    "36个药品"
                ],
                "sentiment_score": 0.7,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "original_text": "白云山(00874.HK)：全资子公司收到36个药品再注册批件",
            "scores": {
                "News_content": "白云山(00874.HK)：全资子公司收到36个药品再注册批件",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "orginal_text": "白云山(600332.SH)：全资子公司收到苯甲酸雌二醇注射液等36个药品的《药品再注册批件》",
            "features": {
                "keywords": [
                    "白云山",
                    "药品再注册",
                    "全资子公司",
                    "苯甲酸雌二醇注射液",
                    "36个药品"
                ],
                "sentiment_score": 0.7,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "original_text": "白云山(600332.SH)：全资子公司收到苯甲酸雌二醇注射液等36个药品的《药品再注册批件》",
            "scores": {
                "News_content": "白云山(600332.SH)：全资子公司收到苯甲酸雌二醇注射液等36个药品的《药品再注册批件》",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        }
    ]
]